Selank vs Semax

Overview

Selank and Semax are synthetic peptides developed in Russia during the Soviet era. Both have been approved in Russia for specific indications but are not approved by the FDA, EMA, or other major Western regulatory agencies.

Important: Neither peptide is approved outside of Russia. Products sold internationally are typically research chemicals with uncertain quality.

Key Facts

Aspect	Selank	Semax
Origin	Russia (1990s)	Russia (1980s)
Class	Tuftsin analog	ACTH 4-10 analog
Administration	Intranasal	Intranasal
Russian Approval	Yes (anxiolytic)	Yes (nootropic, stroke)
FDA Status	Not approved	Not approved

Structure and Origin

Selank

• Synthetic peptide based on tuftsin (immunomodulatory peptide)
• Structure: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• 7 amino acids
• Developed at Institute of Molecular Genetics, Moscow

Semax

• Synthetic fragment of ACTH (adrenocorticotropic hormone)
• Based on ACTH 4-7 with added Pro-Gly-Pro sequence
• 7 amino acids
• Developed at Institute of Molecular Genetics, Moscow

Mechanism Comparison

Aspect	Selank	Semax
Primary Target	GABA system	Melanocortin system
Secondary Effects	Dopamine, serotonin modulation	BDNF, NGF expression
Proposed Action	Anxiolytic, immunomodulatory	Nootropic, neuroprotective
Receptor Binding	GABAergic modulation	MC4R and other mechanisms

Proposed Mechanisms (Preclinical)

Selank:

• Modulates GABA-A receptor function
• Affects enkephalin degradation
• May influence monoamine systems
• Claimed immunomodulatory effects via tuftsin pathway

Semax:

• ACTH fragment without hormonal effects
• Proposed to increase BDNF expression
• May affect dopaminergic pathways
• Claimed neuroprotective effects

Evidence Quality

Selank Research

Source	Quantity	Quality
Russian journals	Numerous	Often not peer-reviewed to Western standards
Western journals	Very few	Limited replication
Human trials	Some in Russia	Methodology questions
Preclinical	Multiple	Mostly from Russian labs

Key limitations:

• Most research published in Russian-language journals
• Limited independent Western replication
• Clinical trial methodology unclear
• Potential publication bias

Semax Research

Source	Quantity	Quality
Russian journals	Extensive	Variable quality
Western journals	More than Selank	Still limited
Human trials	Multiple in Russia	Methodology varies
Preclinical	Numerous	Mostly Russian institutions

Key findings (claimed):

• Studies in stroke, cognitive impairment
• Some BDNF expression data
• Neuroprotection in animal models
• Human efficacy claims not independently verified

Evidence Strength Comparison

Factor	Selank	Semax
Western peer-reviewed	Very low	Low
Independent replication	Minimal	Limited
Controlled human trials	Few	Some
Overall quality	Very low	Low

Claimed Effects

Selank (Not Verified by Western Regulators)

Claim	Evidence Level
Anxiety reduction	Low (Russian trials)
Stress adaptation	Very low
Cognitive enhancement	Very low
Immunomodulation	Very low

Semax (Not Verified by Western Regulators)

Claim	Evidence Level
Cognitive enhancement	Low (Russian trials)
Stroke recovery	Low (Russian use)
Neuroprotection	Very low
ADHD symptoms	Very low

Russian Approval Context

Selank

• Approved in Russia for anxiety, asthenic conditions
• Available as nasal spray (0.15%)
• Prescribed for generalized anxiety
• Not recognized by international regulatory bodies

Semax

• Approved in Russia for:
  • Cognitive disorders
  • Stroke recovery
  • ADHD (in children)
• Available as nasal drops (0.1%, 1%)
• Not recognized by international regulatory bodies

Why No Western Approval

Factor	Explanation
Trial standards	Russian trials may not meet FDA/EMA requirements
Independent data	Lack of replication outside Russian institutions
Commercial interest	No Western pharma pursuing development
Regulatory path	Would require new trials to Western standards

Safety Information

Selank (Limited Data)

Aspect	Information
Common side effects	Fatigue, headache (reported)
Serious concerns	Unknown (limited data)
Drug interactions	Unknown
Long-term effects	Unknown

Semax (Limited Data)

Aspect	Information
Common side effects	Nasal irritation (reported)
Serious concerns	Unknown (limited data)
Drug interactions	Unknown
Long-term effects	Unknown

Practical Comparison

Factor	Selank	Semax
Primary use (claimed)	Anxiety	Cognition
Administration	Intranasal	Intranasal
Availability	Research chemical	Research chemical
Quality assurance	None	None

Modified Forms

NA-Selank and NA-Semax

Some sources sell “N-Acetyl” forms:

• Claimed improved stability
• Claimed improved bioavailability
• Even less research than parent compounds
• Greater uncertainty about effects

Summary

Factor	Selank	Semax
Evidence quality	Very low	Low
Mechanism	GABA modulation	Melanocortin/BDNF
Primary claim	Anxiolytic	Nootropic
Russian approval	Yes	Yes
Western approval	No	No
Independent verification	Minimal	Limited

Both peptides have approval only in Russia. Western scientific evidence is insufficient to support efficacy claims. Products available internationally are unregulated research chemicals.

---

This comparison is for educational purposes only. Neither compound is approved by the FDA or EMA. Products sold as research chemicals have uncertain quality and safety.